{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:45:55Z","timestamp":1790721955484,"version":"4.1.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Define the role of diagnostic PET in the staging of patients with lymphoma. Discuss the role of PET in the evaluation of residual masses in patients with lymphoma. Explain the limitations of PET scanning and the special situations where PET scanning has been used in the evaluation of patients with lymphoma.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Positron emission tomography (PET) is a novel functional imaging technique that provides several inherent advantages over conventional nuclear scintigraphy. Several studies have suggested a role for PET using the positron emitter fluorine-18 in the diagnosis and follow-up of patients with lymphoma. This review summarizes the existing data evaluating the role of 2-fluoro-2-deoxy-D-glucose (FDG)-PET in both the staging and follow-up of patients with lymphoma. Most studies of PET involve patients with either Hodgkin's disease or diffuse large B-cell non-Hodgkin's lymphoma. PET detects more disease sites above and below the diaphragm on staging of lymphoma than gallium scintigraphy and may have particular utility in the evaluation of the spleen. Moreover, persistently positive PET scans during and after chemotherapy appear to have a high sensitivity for predicting subsequent relapse. A negative PET scan at the end of therapy provides very favorable prognostic information. Persistently positive PET scans at the end of therapy warrant close follow-up or additional diagnostic procedures, since some of those patients may remain in prolonged remission. Clearly, additional studies, including prospective blinded trials and cost-effectiveness analyses, are warranted to determine which subsets of patients with lymphoma ultimately will benefit from this modality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.8-5-438","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"438-447","source":"Crossref","is-referenced-by-count":76,"title":["PET Scans in the Staging of Lymphoma: Current Status"],"prefix":"10.1093","volume":"8","author":[{"given":"Jonathan W.","family":"Friedberg","sequence":"first","affiliation":[{"name":"Lymphoma Program, James P. Wilmot Cancer Center, University of Rochester, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaseem","family":"Chengazi","sequence":"additional","affiliation":[{"name":"Lymphoma Program, James P. Wilmot Cancer Center, University of Rochester, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,10,1]]},"reference":[{"key":"2021122209332046000_R1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"2021122209332046000_R2","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.1999.17.11.3577","article-title":"Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease [see comments]","volume":"17","author":"Ng","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209332046000_R3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/beha.2002.0217","article-title":"Pre- and post-treatment evaluation of non-Hodgkin's lymphoma","volume":"15","author":"Mavromatis","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122209332046000_R4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.1997.15.4.1631","article-title":"Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy","volume":"15","author":"Janicek","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122209332046000_R5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/5.suppl_2.S59","article-title":"The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy","volume":"5","author":"Hagemeister","year":"1994","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.1997.15.2.518","article-title":"Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients","volume":"15","author":"Salloum","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122209332046000_R7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0001-2998(05)80007-8","article-title":"The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients","volume":"25","author":"Front","year":"1995","journal-title":"Semin Nucl Med"},{"key":"2021122209332046000_R8","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s002590000340","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?","volume":"27","author":"Kostakoglu","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"2021122209332046000_R9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2001.19.9.2504","article-title":"Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center","volume":"19","author":"Tucker","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209332046000_R10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1040-8428(01)00127-5","article-title":"[18F]-FDG positron imaging in clinical management of lymphoma patients","volume":"38","author":"Talbot","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122209332046000_R11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1042819021000040251","article-title":"Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma","volume":"44","author":"Weihrauch","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2021122209332046000_R12","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"2021122209332046000_R13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1023\/A:1008312726163","article-title":"Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type","volume":"10","author":"Hoffmann","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000070290","article-title":"18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma","volume":"64","author":"Hoffmann","year":"2003","journal-title":"Oncology"},{"key":"2021122209332046000_R15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1011169332265","article-title":"Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)","volume":"12","author":"Jerusalem","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/108497801753131372","article-title":"Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)","volume":"16","author":"Najjar","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"2021122209332046000_R17","first-page":"1790","article-title":"Predicting malignancy grade with PET in non-Hodgkin's lymphoma","volume":"36","author":"Rodriguez","year":"1995","journal-title":"J Nucl Med"},{"key":"2021122209332046000_R18","first-page":"325","article-title":"Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity","volume":"33","author":"Okada","year":"1992","journal-title":"J Nucl Med"},{"key":"2021122209332046000_R19","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V86.9.3522.bloodjournal8693522","article-title":"Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose","volume":"86","author":"Lapela","year":"1995","journal-title":"Blood"},{"key":"2021122209332046000_R20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1259\/bjr.73.869.10884743","article-title":"The impact of FDG positron emission tomography imaging on the management of lymphomas","volume":"73","author":"Shah","year":"2000","journal-title":"Br J Radiol"},{"key":"2021122209332046000_R21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1008368330519","article-title":"2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution","volume":"11","author":"Partridge","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008486928190","article-title":"Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease","volume":"9","author":"Bangerter","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0002-9343(01)01117-2","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma","volume":"112","author":"Wirth","year":"2002","journal-title":"Am J Med"},{"key":"2021122209332046000_R24","first-page":"321","article-title":"Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma","volume":"9","author":"Shen","year":"2002","journal-title":"Oncol Rep"},{"key":"2021122209332046000_R25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/cncr.10336","article-title":"Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma","volume":"94","author":"Kostakoglu","year":"2002","journal-title":"Cancer"},{"key":"2021122209332046000_R26","article-title":"FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison","volume-title":"Leuk Lymphoma","author":"Friedberg","year":"2003"},{"key":"2021122209332046000_R27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5","article-title":"2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial","volume":"91","author":"Buchmann","year":"2001","journal-title":"Cancer"},{"key":"2021122209332046000_R28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4","article-title":"Whole body positron emission tomography in the treatment of Hodgkin disease","volume":"91","author":"Hueltenschmidt","year":"2001","journal-title":"Cancer"},{"key":"2021122209332046000_R29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3816\/CLM.2000.n.007","article-title":"Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography","volume":"1","author":"Kostakoglu","year":"2000","journal-title":"Clin Lymphoma"},{"key":"2021122209332046000_R30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1148\/radiology.203.3.9169707","article-title":"Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging","volume":"203","author":"Moog","year":"1997","journal-title":"Radiology"},{"key":"2021122209332046000_R31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/028418699432969","article-title":"Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest","volume":"38","author":"Bangerter","year":"1999","journal-title":"Acta Oncol"},{"key":"2021122209332046000_R32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0002-9343(02)01044-6","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care","volume":"112","author":"Kaplan","year":"2002","journal-title":"Am J Med"},{"key":"2021122209332046000_R33","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s002590000323","article-title":"Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography","volume":"27","author":"Klose","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"2021122209332046000_R34","first-page":"4464","article-title":"Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose","volume":"91","author":"Romer","year":"1998","journal-title":"Blood"},{"key":"2021122209332046000_R35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.2002.20.5.1398","article-title":"Standardized uptake value of 2-[(18)f] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy","volume":"20","author":"Allal","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209332046000_R36","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu","year":"2002","journal-title":"J Nucl Med"},{"key":"2021122209332046000_R37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"key":"2021122209332046000_R38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2001.03147.x","article-title":"Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma","volume":"115","author":"Naumann","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122209332046000_R39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209332046000_R40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009113384","article-title":"18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT","volume":"39","author":"Mikhaeel","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"2021122209332046000_R41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0959-8049(99)00249-X","article-title":"Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?","volume":"36","author":"Maisey","year":"2000","journal-title":"Eur J Cancer"},{"key":"2021122209332046000_R42","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1023\/A:1008327127033","article-title":"The role of positron emission tomography (PET) in the management of lymphoma patients [see comments]","volume":"10","author":"Zinzani","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R43","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","article-title":"Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease","volume":"98","author":"Weihrauch","year":"2001","journal-title":"Blood"},{"key":"2021122209332046000_R44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdg011","article-title":"Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease","volume":"14","author":"Jerusalem","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122209332046000_R45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s002590050356","article-title":"Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma","volume":"26","author":"Kotzerke","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"2021122209332046000_R46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058482","article-title":"Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease","volume":"34","author":"Wiedmann","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"2021122209332046000_R47","first-page":"1393","article-title":"Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma","volume":"8","author":"Dittmann","year":"2001","journal-title":"Oncol Rep"},{"key":"2021122209332046000_R48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3816\/CLM.2001.n.006","article-title":"Staging and monitoring response to treatment in primary non-Hodgkin's lymphoma of bone marrow using (18)F-fluorodeoxyglucose positron emission tomography","volume":"1","author":"Matthies","year":"2001","journal-title":"Clin Lymphoma"},{"key":"2021122209332046000_R49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1148\/radiology.206.2.9457202","article-title":"Extranodal malignant lymphoma: detection with FDG PET versus CT","volume":"206","author":"Moog","year":"1998","journal-title":"Radiology"},{"key":"2021122209332046000_R50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.1998.16.2.603","article-title":"18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow","volume":"16","author":"Moog","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209332046000_R51","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V91.9.3340","article-title":"Detection of lymphoma in bone marrow by whole-body positron emission tomography","volume":"91","author":"Carr","year":"1998","journal-title":"Blood"},{"key":"2021122209332046000_R52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00003072-200202000-00018","article-title":"Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma","volume":"27","author":"Gundlapalli","year":"2002","journal-title":"Clin Nucl Med"},{"key":"2021122209332046000_R53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006202402010","article-title":"Positron emission tomography in patients with primary CNS lymphomas","volume":"43","author":"Roelcke","year":"1999","journal-title":"J Neurooncol"},{"key":"2021122209332046000_R54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00003072-200208000-00005","article-title":"F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease","volume":"27","author":"Rini","year":"2002","journal-title":"Clin Nucl Med"},{"key":"2021122209332046000_R55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.leu.2402342","article-title":"Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation","volume":"16","author":"Becherer","year":"2002","journal-title":"Leukemia"},{"key":"2021122209332046000_R56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2002-12-3842","article-title":"Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation","volume":"102","author":"Spaepen","year":"2003","journal-title":"Blood"},{"key":"2021122209332046000_R57","first-page":"987","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","author":"A predictive model for aggressive non-Hodgkin's lymphoma","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122209332046000_R58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.bmt.1703607","article-title":"Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma","volume":"30","author":"Cremerius","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"2021122209332046000_R59","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1083-8791(01)80012-4","article-title":"The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"7","author":"Friedberg","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122209332046000_R60","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1067\/mjd.2002.124076","article-title":"Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas","volume":"47","author":"Shapiro","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2021122209332046000_R61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/gut.52.3.347","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma","volume":"52","author":"Hoffmann","year":"2003","journal-title":"Gut"},{"key":"2021122209332046000_R62","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/j.1572-0241.2001.04061.x","article-title":"18F-Fluorodeoxyglucose PET in a patient with primary small bowel lymphoma: the only sensitive method of imaging","volume":"96","author":"Ullerich","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2021122209332046000_R63","first-page":"1407","article-title":"FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma","volume":"40","author":"Moog","year":"1999","journal-title":"J Nucl Med"},{"key":"2021122209332046000_R64","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-002-0861-y","article-title":"[(18)F]FDG in childhood lymphoma: clinical utility and impact on management","volume":"29","author":"Montravers","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122209332046000_R65","first-page":"2681","article-title":"3\u2032-[18F]fluoro-3\u2032-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease","volume":"63","author":"Wagner","year":"2003","journal-title":"Cancer Res"},{"key":"2021122209332046000_R66","first-page":"533","article-title":"Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG","volume":"44","author":"Hustinx","year":"2003","journal-title":"J Nucl Med"},{"key":"2021122209332046000_R67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-001-0390-y","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease","volume":"81","author":"Weihrauch","year":"2002","journal-title":"Ann Hematol"},{"key":"2021122209332046000_R68","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.8-5-438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.8-5-438","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/5\/438\/41840492\/oncolo_8_5_438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/5\/438\/41840492\/oncolo_8_5_438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:51:38Z","timestamp":1640191898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/8\/5\/438\/6387560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2003,10,1]]},"published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.8-5-438","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,10,1]]},"published":{"date-parts":[[2003,10,1]]}}}